Evolus Inc. (EOLS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Evolus Inc. (EOLS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

9.45

-0.35 (-3.57%)

At close: Jan 14, 2025, 3:59 PM

9.47

0.26%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	3.82
Market Cap	598.07M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.91
PE Ratio (ttm)	-10.38
Forward PE	n/a
Analyst	Buy

Ask	12.85
Volume	636,188
Avg. Volume (20D)	630,890
Open	9.80
Previous Close	9.80
Day's Range	9.25 - 9.89
52-Week Range	9.25 - 17.82
Beta	undefined

About EOLS

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California....

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Feb 8, 2018

Employees 322

Stock Exchange NASDAQ

Ticker Symbol EOLS

Website https://www.evolus.com

Analyst Forecast

According to 6 analyst ratings, the average rating for EOLS stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 154.10% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Evolus Inc. is scheduled to release its earnings on Mar 6, 2025, during market hours.
Analysts project revenue of $77.23M, reflecting a 26.61% YoY growth and earnings per share of 0, making a -100.00% decrease YoY.

Why Price Moved

5 months ago · Source

+13.04%

Evolus shares are trading higher after the company... Unlock content with Pro Subscription

5 months ago · Source

+1.89%

Evolus shares are trading higher. The company reported Q2 financial results.

News

21 hours ago · seekingalpha.com

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

I previously rated Evolus, Inc. stock a “Buy” due to its litigation settlement with AbbVie, strong revenue targets, and promising product performance. Despite positive updates, Evolus stock fell sharp...

1 month ago · businesswire.com

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in Novemb...

1 month ago · zacks.com

Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher

Evolus (EOLS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall St...

2 months ago · zacks.com

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)

Evolus (EOLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co...

2 months ago · zacks.com

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.19 per share a year ago.

2 months ago · businesswire.com

Evolus Reports Third Quarter 2024 Results

2 months ago · businesswire.com

Evolus to Participate in Stifel 2024 Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...

2 months ago · businesswire.com

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Dev...

2 months ago · zacks.com

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.